A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover’s Review of Emerging Medical Ventures
This month's profile group: Nanotechnology: A Balm for the Challenges of Drug Delivery
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.
A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover’s Review of Emerging Medical Ventures
This month's profile group: Nanotechnology: A Balm for the Challenges of Drug Delivery
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.